Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
At the start of the SARS-CoV-2 pandemic, we and others produced guidance for people living with IBD and their clinical teams on behalf of the British Society of Gastroenterology.1 This included publication of a risk grid based on key variables that were believed to increase the risk of adverse COVID-19 outcomes. The grid has been widely adopted providing a useful framework for patients, clinicians and policymakers but is now no longer relevant and should not be used.
The risk grid was the basis for categorisation into clinically vulnerable and extremely clinically vulnerable grouping informing those who should follow ‘shielding’ recommendations. It subsequently informed prioritisation for vaccination against SARS-CoV-2 and more recently use of antivirals and monoclonal antibody therapies directed against SARS-C0V-2 . We developed the grid in April 2020 based on early information about the …
Twitter @charlie_lees, @DrChrisLamb
Contributors All authors developed the recommendation. CWS drafted the manuscript. All authors critically reviewed the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.